July 2025
1. SCHMITZ J, Gaskill E, Price S, Cao B, et al
   Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.
   Bone Marrow Transplant. 2025 Jul 5. doi: 10.1038/s41409-025-02670.
   

   >> Share

   
   May 2025
2. KUNO M, Tanaka T, Maeshima AM, Takamaru H, et al
   Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic cell transplantation.
   Bone Marrow Transplant. 2025 May 20. doi: 10.1038/s41409-025-02621.
   

   >> Share

   
   
3. LIBERATORE C, D'Uva M, Natale A, Guardalupi F, et al
   Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab.
   Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02624.
   

   >> Share

   
   
4. ZAMORA D, Xie H, Wong E, Santiano C, et al
   ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients.
   Bone Marrow Transplant. 2025 May 6. doi: 10.1038/s41409-025-02611.
   

   >> Share

   
   March 2025
5. ZHEN S, Liu L, Zhang X, Wang J, et al
   Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegaloviru
   Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02542.
   

   >> Share

   
   January 2025
6. WANG Q, Liu M, Zhang S, Gao L, et al
   Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
   Bone Marrow Transplant. 2025 Jan 7. doi: 10.1038/s41409-024-02502.
   

   >> Share

   
   November 2024
7. ALEXANDER T, Badoglio M, Labopin M, Daikeler T, et al
   Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP).
   Bone Marrow Transplant. 2024 Nov 7. doi: 10.1038/s41409-024-02461.
   

   >> Share

   
   July 2024
8. ESTEVE M, Albert E, Gimenez E, Colomer E, et al
   Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis.
   Bone Marrow Transplant. 2024 Jul 20. doi: 10.1038/s41409-024-02376.
   

   >> Share

   
   May 2024
9. PFEIFFER T, Lockowitz CR, Shenoy S, Mavers M, et al
   Letermovir as cytomegalovirus prophylaxis in children undergoing allogeneic hematopoietic cell transplantation.
   Bone Marrow Transplant. 2024 May 21. doi: 10.1038/s41409-024-02315.
   

   >> Share

   
   January 2024
10. GALAVERNA F, Baccelli F, Zama D, Tridello G, et al
    Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02209.
    

    >> Share

    
    
11. BASHEY SZ, Solomon SR, Zhang X, Morris LE, et al
    Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-024-02201.
    

    >> Share

    
    November 2023
12. MALAGOLA M, Radici V, Farina M, Pellizzeri S, et al
    Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Nov 29. doi: 10.1038/s41409-023-02158.
    

    >> Share

    
    October 2023
13. MALAGOLA M, Radici V, Farina M, Pellizzeri S, et al
    CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2023 Oct 19. doi: 10.1038/s41409-023-02124.
    

    >> Share

    
    
14. OROFINO G, Xue E, Doglio M, Noviello M, et al
    Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir.
    Bone Marrow Transplant. 2023;58:1104-1111.
    

    >> Share

    
    August 2023
15. KABUT T, Weinbergerova B, Folber F, Lengerova M, et al
    High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience.
    Bone Marrow Transplant. 2023 Aug 23. doi: 10.1038/s41409-023-02081.
    

    >> Share

    
    
16. PRUITT A, Gao F, De Togni E, Cochran H, et al
    Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation.
    Bone Marrow Transplant. 2023;58:855-862.
    

    >> Share

    
    March 2023
17. EBERHARDT KA, Jung V, Knops E, Heger E, et al
    CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
    Bone Marrow Transplant. 2023 Mar 3. doi: 10.1038/s41409-023-01944.
    

    >> Share

    
    December 2022
18. SUN X, Fu H, Wang C, Zhang Y, et al
    Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection.
    Bone Marrow Transplant. 2022 Dec 1. doi: 10.1038/s41409-022-01880.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share